Nicholas Bodor

Nicholas Bodor, Ph.D.

Graduate Research Professor Emeritus

Department: Pharmaceutics
Business Email: bodor@cop.ufl.edu

About Nicholas Bodor

Bodor received his B.S./M.S. degree in Organic Chemistry in 1959 at Bolyai University in Transylvania, and his Ph.D. degree in 1965 from the University of Babes-Bolyai, Cluj and the Romanian National Academy of Sciences. He was a Group Leader at the Pharmacochemical Research Institute in Romania until 1968, when he received a R. A. Welch Fellowship at the University of Texas in Austin. In 1972 he became a Senior Research Scientist at ALZA Laboratories in Lawrence, Kansas, which later became INTERx Research Corporation, where he was Director of Research, as well as an Adjunct Professor at the University of Kansas until 1978.

Bodor joined the University of Florida in Gainesville in 1979 as Professor and Chairman of the Medicinal Chemistry Department. He was promoted to Graduate Research Professor of the university in 1983. He is the Executive Director of the Center for Drug Discovery in the College of Pharmacy. He also holds appointments as Affiliate Graduate Research Professor in the Department of Chemistry in the College of Liberal Arts and the Department of Ophthalmology in the College of Medicine at the University. During his tenure at the University of Florida, he has supervised the training of more than 50 doctoral students and over 100 postdoctoral level research associates and fellows. In February 2000, he took a leave of absence from his academic posts at UF to accept a position as Senior Vice President of Basic Research and Drug Discovery at the IVAX Corporation. Bodor served as Chief Scientific Officer of the IVAX Corporation, Managing Director of the IVAX Drug Research Institute, Budapest, Hungary, as well as President of the IVAX Research Institute until October 2005, when he returned to the University of Florida as Graduate Research Professor and Executive Director of the Center for Drug Discovery.

Inducted into the American chemical Society’s Hall of Fame, Division of Medicinal Chemistry.

He is an elected Fellow of the Academy of Pharmaceutical Sciences, the American Association of Pharmaceutical Scientists, the American Association for the Advancement of Science, and American College of Clinical Pharmacology. He is also an Honorary Member of the Hungarian Chemical Society and the Panhellenic Society of Pharmacists. Among other honors, Dr. Bodor has been named “The 1984 Florida Scientist of the Year” and received the first AAPS Research Achievement Award in Medicinal and Natural Product Chemistry in 1988, as well as the APhA Research Achievement Award in Pharmaceutical and Medicinal Chemistry in 1989. In 1989 he also received an honorary Doctor of Science degree from the Technical University of Budapest, and then was awarded the Doctor Honoris Causa degree from the Medical University of Debrecen in 1990. In 1994 he was named the first recipient of the Nagai Foundation Tokyo International Fellowship. In 1995 he was elected to the Hungarian National Academy of Sciences. He was named by the American Chemical Society as the 1996 recipient of the Leo Friend Award in recognition of his article entitled, “Design of Biologically Safer Chemicals,” published in Chemtech, October 1995. He is the first College of Pharmacy faculty member to receive a Professorial Excellence Award, given by the University of Florida in 1996. The AACP selected Dr. Bodor as the recipient of the 1997 Volwiler Research Achievement Award. In April 2000, Bodor was named the V. Ravi Chandran Professor in Drug Design and Targeting of the UF College of Pharmacy, the first recipient of this endowed professorship. In February 2002, he was elected a Fellow of the World Innovation Foundation. In 2004, Ferenc Madl, President of Hungary, awarded Bodor the Gold Cross of Merit of the Hungarian Republic. An honorary Doctor of Science degree was conferred upon Bodor by the University of Florida in 2005. In 2007, the American Association of Pharmaceutical Scientists awarded Bodor with a Distinguished Pharmaceutical Scientist Award.

Research Profile

Bodor’s main research interests include design of drugs with improved therapeutic index, design of new chemical delivery systems, computer-assisted drug design, drug transport and metabolism, and theoretical and mechanistic organic chemistry. He has published more than 500 research articles, holds more than 180 patents, and is on the editorial boards of several international scientific journals. Bodor is the founder and organizer of a biennial series of symposia entitled, The Retrometabolism Based Drug Design and Targeting Conference, which is dedicated to the study of the drug optimization strategies that he has pioneered. The soft steroid Loteprednol Etabonate, he designed, is on the market in the U.S. and other countries. Other drugs he has designed using the retrometabolic concepts are in advanced clinical development.

Publications

2021
Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs.
Expert opinion on drug metabolism & toxicology. 17(5):555-580 [DOI] 10.1080/17425255.2021.1902986. [PMID] 33703995.
2021
Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report)
Pure and Applied Chemistry. 93(3):273-403 [DOI] 10.1515/pac-2018-0208.
2020
Modulation of expression/function of intestinal P-glycoprotein under disease states.
Expert opinion on drug metabolism & toxicology. 16(1):59-78 [DOI] 10.1080/17425255.2020.1701653. [PMID] 31821048.
2019
Identification of Major Esterase Involved in Hydrolysis of Soft Anticholinergic (2R3’R-SGM) Designed From Glycopyrrolate in Human and Rat Tissues.
Journal of pharmaceutical sciences. 108(8):2791-2797 [DOI] 10.1016/j.xphs.2019.03.030. [PMID] 30954525.
2017
Identification of esterase involved in the metabolism of two corticosteroid soft drugs.
Biochemical pharmacology. 127:82-89 [DOI] 10.1016/j.bcp.2016.12.010. [PMID] 28017774.
2017
Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids.
The Journal of pharmacy and pharmacology. 69(12):1745-1753 [DOI] 10.1111/jphp.12819. [PMID] 28980320.
2016
Brain-Targeting Chemical Delivery Systems and Their Cyclodextrin-Based Formulations in Light of the Contributions of Marcus E. Brewster.
Journal of pharmaceutical sciences. 105(9):2589-2600 [DOI] 10.1016/j.xphs.2016.04.007. [PMID] 27209462.
2016
Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin.
Journal of pharmaceutical sciences. 105(9):2873-2878 [DOI] 10.1016/j.xphs.2016.03.028. [PMID] 27179671.
2012
The Effects of Delta(L)-Cortienic Acid On Skin Blanching, Pharmacokinetics and Stability of Loteprednol Etabonate
Die Pharmazie. 67(5):406-410 [DOI] 10.1691/ph.2012.1693. [PMID] 22764572.
2010
Feasibility of Localized Immunosuppression: 1. Exploratory Studies With Glucocorticoids in a Biohybrid Device Designed for Cell Transplantation
Die Pharmazie. 65(6):421-428 [DOI] 10.1691/ph.2010.0525R. [PMID] 20614690.
2010
Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant.
Die Pharmazie. 65(6):429-35 [PMID] 20614691.
2010
Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats.
Die Pharmazie. 65(6):412-6 [PMID] 20614688.
2010
Recent advances in retrometabolic drug design (RMDD) and development.
Die Pharmazie. 65(6):395-403 [PMID] 20614685.
2008
Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
The Journal of pharmacy and pharmacology. 60(3):291-7 [DOI] 10.1211/jpp.60.3.0003. [PMID] 18284808.
2008
Retrometabolic Drug Design: Principles and Recent Developments
Pure and Applied Chemistry. 80(8):1669-1682 [DOI] 10.1351/pac200880081669.
2008
Selective Reduction of Trigonellyl Group To the Corresponding Dihydropyridine in the Presence of Disulfide Group
Bulletin of the Korean Chemical Society. 29:479-482
2008
Soft Corticosteroids for Local Immunosuppression: Exploring the Possibility for the Use of Loteprednol Etabonate for Islet Transplantation
Die Pharmazie. 63(3):226-232 [DOI] 10.1691/ph.2008.7774. [PMID] 18444512.
2008
Stereoisomers of N-Substituted Soft Anticholinergics and Their Zwitterion Metabolite Based On Glycopyrrolate – Syntheses and Pharmacological Evaluations
Die Pharmazie. 63(3):200-209 [DOI] 10.1691/ph.2008.7775. [PMID] 18444508.
2007
Novel, cell-penetrating molecular transporters with flexible backbones and permanently charged side-chains.
The Journal of pharmacy and pharmacology. 59(8):1065-76 [PMID] 17725848.
2006
Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids.
Current pharmaceutical design. 12(25):3241-60 [PMID] 17020532.
2006
Soft quaternary anticholinergics: comprehensive quantitative structure-activity relationship (QSAR) with a linearized biexponential (LinBiExp) model.
Journal of medicinal chemistry. 49(3):883-91 [PMID] 16451054.
2005
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.
The AAPS journal. 7(4):E820-33 [PMID] 16594634.
2005
Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics.
Pharmaceutical research. 22(12):2035-44 [PMID] 16170596.
2005
Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.
Journal of pharmacokinetics and pharmacodynamics. 32(3-4):377-400 [PMID] 16320099.
2004
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
Molecular biotechnology. 26(2):123-32 [PMID] 14764938.
2004
New evidence for the selective, long-lasting central effects of the brain-targeted estradiol, Estredox.
Pharmacology, biochemistry, and behavior. 77(3):423-9 [PMID] 15006452.
2003
Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics.
Pharmaceutical research. 20(10):1681-9 [PMID] 14620526.
2003
Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166).
The Journal of pharmacology and experimental therapeutics. 307(1):83-92 [PMID] 12893841.
2002
Barriers to remember: brain-targeting chemical delivery systems and Alzheimer’s disease.
Drug discovery today. 7(14):766-74 [PMID] 12547033.
2002
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
Methods in molecular biology (Clifton, N.J.). 186:301-12 [PMID] 12013781.
2002
In vitro and in vivo evaluations of dihydroquinoline- and dihydroisoquinoline-based targetor moieties for brain-specific chemical delivery systems.
Journal of drug targeting. 10(1):63-71 [PMID] 11996088.
2002
Synthesis and biological evaluations of brain-targeted chemical delivery systems of [Nva2]-TRH.
The Journal of pharmacy and pharmacology. 54(7):945-50 [PMID] 12162713.
2001
Design, in vitro stability, and ocular hypotensive activity of t-butalone chemical delivery systems.
Journal of pharmaceutical sciences. 90(8):1026-33 [PMID] 11536206.
2001
Intraocular pressure-lowering activity and in vivo disposition of dipivalyl terbutalone in rabbits.
Drug development and industrial pharmacy. 27(2):137-41 [PMID] 11266225.
2000
Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate.
Die Pharmazie. 55(3):206-9 [PMID] 10756542.
2000
Recent advances in retrometabolic drug design and targeting approaches.
Die Pharmazie. 55(3):163-6 [PMID] 10756533.
2000
Soft drug design: general principles and recent applications.
Medicinal research reviews. 20(1):58-101 [PMID] 10608921.
2000
Synthesis and pharmacological evaluation of prodrugs of valproic acid.
Die Pharmazie. 55(3):184-6 [PMID] 10756537.
2000
Targeting drugs to the brain by redox chemical delivery systems.
Medicinal research reviews. 20(5):367-416 [PMID] 10934349.
1999
Chemical delivery systems: evaluation of physicochemical properties and enzymatic stability of phenylephrone derivatives.
Pharmaceutical development and technology. 4(2):189-98 [PMID] 10231880.
1999
Recent advances in retrometabolic design approaches.
Journal of controlled release : official journal of the Controlled Release Society. 62(1-2):209-22 [PMID] 10518653.
1997
Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat.
Journal of neurosurgery. 87(5):724-30 [PMID] 9347981.
1996
Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 12(2):159-67 [PMID] 8773932.
1995
Theoretical studies on the structures of natural and alkylated cyclodextrins.
Journal of pharmaceutical sciences. 84(3):330-6 [PMID] 7616373.
1995
Tissue distribution of LY231617, an antioxidant with neuroprotectant activity, in the rat.
Journal of pharmaceutical sciences. 84(7):791-3 [PMID] 7562425.
1994
Improved delivery through biological membranes. LXI: Design, synthesis, and evaluation of a lipolol-based intradermal drug targeting system for 5-fluorouracil.
Cancer biotherapy. 9(3):245-52 [PMID] 7820186.
1994
In vitro evaluation of a controlled-release site-specific diisovaleryl tert-butalone chemical delivery system for the eye.
Journal of pharmaceutical sciences. 83(3):450-3 [PMID] 8207701.
1993
Soft drugs 15: mydriatic activity and transcorneal penetration of phenylsuccinic soft analogs of methscopolamine as short acting mydriatics.
Current eye research. 12(6):501-6 [PMID] 8359027.
1993
Soft drugs–XIV. Synthesis and anticholinergic activity of soft phenylsuccinic analogs of methatropine.
Bioorganic & medicinal chemistry. 1(3):183-7 [PMID] 8081850.
1993
Soft drugs–XVI. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine.
Bioorganic & medicinal chemistry. 1(5):327-32 [PMID] 8081862.
1993
Soft drugs. 12: Design, syntheses and evaluation of soft anticholinergics.
Drug design and discovery. 10(1):11-21 [PMID] 8399991.
1993
Soft drugs. 13: Design and evaluation of phenylsuccinic analogs of scopolamine as soft anticholinergics.
Drug design and discovery. 10(1):1-9 [PMID] 8399990.
1993
Synthesis and in vitro dopaminergic activity of (2-aminoethyl)-1-hydroxy-2-pyridone type dopamine analogs.
Drug design and discovery. 10(1):35-44 [PMID] 8104516.
1991
A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat.
Pharmaceutical research. 8(9):1180-5 [PMID] 1788164.
1991
Novel soft steroids: effects on cell growth in vitro and on wound healing in the mouse.
Steroids. 56(8):434-9 [PMID] 1788862.
1990
A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog.
Pharmaceutical research. 7(8):879-83 [PMID] 2235886.
1989
Evidence for prolonged suppression of stress-induced release of adrenocorticotropic hormone and corticosterone with a brain-enhanced dexamethasone-redox delivery system.
Neuroendocrinology. 50(1):9-16 [PMID] 2547177.
1989
Improved anticonvulsant activity of phenytoin by a redox brain delivery system I: Synthesis and some properties of the dihydropyridine derivatives.
Journal of pharmaceutical sciences. 78(8):609-16 [PMID] 2778665.
1989
Improved anticonvulsant activity of phenytoin by a redox brain delivery system. III: Brain uptake and pharmacological effects.
Journal of pharmaceutical sciences. 78(10):837-43 [PMID] 2600790.
1988
A redox system for brain targeted estrogen delivery causes chronic body weight decrease in rats.
Life sciences. 42(10):1077-84 [PMID] 3347139.

Contact Details

Emails:
Business:
bodor@cop.ufl.edu
Addresses:
Business Mailing:
Ste. 980, Bodor Laboratories, Inc.
4400 Biscayne Blvd.
Miami FL 33137
Business Street:
4400 BISCAYNE BLVD STE 980
MIAMI FL 33137